The latest biotech news

News and Trends 5 May 2023

‘Birth of a chromosome’ could boost cancer and infertility research

Most chromosomes have been around for millions of years. However, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility. The researchers say the findings may lead […]

May 5, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 5 May 2023

Exothera partners with Quantoom and launches DNA business unit

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […]

May 5, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 May 2023

Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […]

May 5, 2023 - 2 minutesmins - By Jim Cornall

Fluorescence microcopy image of gamma delta T cells (green) attacking cancer cells (blue). To get tot he cancer cells, the immune cells need to navigate through a dense extracellular matrix that surrounds the tumor tissue (red). Image: Katrin Raute / University of Freiburg

News and Trends 4 May 2023

Osteoporosis drug helps T cells fight aggressive breast cancer

Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system – and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer, with limited treatment options and a high probability of recurrence. Tumor growth and relapse of TNBC are driven by breast […]

May 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 May 2023

LIfT BioSciences says data show potent killing of pancreatic cancer tumoroids

LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids. The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel), but initially responded positively to […]

May 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 May 2023

World’s first RSV vaccine for older adults gets FDA approval

GSK plc says the US Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. It is the first RSV vaccine for older adults to be approved anywhere in […]

May 4, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 3 May 2023

Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline

Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of […]

May 3, 2023 - 8 minutesmins - By Jim Cornall

News and Trends 3 May 2023

Eterna acquires allogeneic immuno-oncology platform from Exacis

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 May 2023

First drug discovered through 3D bioprinted tissue disease model

Viscient Bio, Inc. has announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. The company said it expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the U.S. […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Cabaletta Bio’s lupus drug cleared for trial

Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to CABA-201. Cabaletta Bio’s CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed […]

May 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 May 2023

FDA fast track for Memo’s kidney transplant infection treatment

Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]

May 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

‘Birth of a chromosome’ could boost cancer and infertility research

Exothera partners with Quantoom and launches DNA business unit

Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals

Osteoporosis drug helps T cells fight aggressive breast cancer

LIfT BioSciences says data show potent killing of pancreatic cancer tumoroids

World’s first RSV vaccine for older adults gets FDA approval

Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline

Eterna acquires allogeneic immuno-oncology platform from Exacis

First drug discovered through 3D bioprinted tissue disease model

Cabaletta Bio’s lupus drug cleared for trial

FDA fast track for Memo’s kidney transplant infection treatment

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!